Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DOP directs NPPA to...

    DOP directs NPPA to fix retail price of Baclofen Oral Solution based on Sun Pharma Complaint

    Farhat NasimWritten by Farhat Nasim Published On 2019-01-25T13:20:06+05:30  |  Updated On 25 Jan 2019 1:20 PM IST
    DOP directs NPPA to fix retail price of Baclofen Oral Solution based on Sun Pharma Complaint

    New Delhi: Through a recent decision, NPPA has been directed by the Department of Pharmaceuticals to refix the retail price of Baclofen Oral Solution after factoring effective (5%) GST rate.


    The decision came in response to a review order that was filed by drug major Sun Pharma challenging the NPPA order that fixed the price of the said formulation at Rs 1.42 per ml


    The orders came following the review application filed by Sun Pharma against the government regulatory body, the National Pharmaceutical Pricing Authority (NPPA). The drug major contended that the retail price of the concerned subject formulation was notified as Rs 1.42 per millilitre. However, the working sheet for the notification was displayed much later on the official website of NPPA. The company even claimed that the working sheet was not made available prior to price notification.


    Further, the firm challenged the tax rate levied on Baclofen. The official central GST rate notified for the drug is 2.5% making the effective GST rate as 5% combining equal central and state share.


    The claimed MRP mentioned in their Form I application of this formulation was Rs 160 for a 100ml pack. In the working sheet, GST of 12% was factored into the calculation of erroneously to arrived claimed retail price of Rs 1.42 per ml which otherwise would have been different had official 5% GST would have been considered. The applicant stated that in the notification on the website of CBEC, the list of goods at 5% GST rate is given, wherein Baclofen is mentioned at S.No.5 in list 1 of Schedule I describing goods charged at 5% GST rate, the company challenged


    "The applicant, therefore, requested to revise the retail price of Baclofen Oral Solution by considering 5% GST.”


    Responding to the allegation NPPA stated that based on para 5 and 15 of DPCO 2013, NPPA uploads the working sheet, if applicable, after notification of the retail price.


    However, on the issue of GST, the regulatory body added that it has noted the issue raised by the firm and the same may be looked into based on the direction of DoP and submission of the requisite documents by the firm.


    After going through the entire case the, DOP directed
    NPPA is hereby directed to refix the retail price of Baclofen Oral Solution after factoring effective (5%) GST rate, within a period of one month from the date of issue of the order.
    Issued on this date, the 10th day of January, 2019.

    Also Read: Sun Pharma takes steps to ease governance concerns
    baclofendept of pharmaceuticalDOPdrug peiceindian pharma newsNational Pharmaceutical Pricing AuthorityNPPApharma newsPharmaceuticalspharmacy newsPharmacy news in Indiarefixretail pricereview applicationreview orderSun Pharma

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok